References
- Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: update 2016. Eur Urol 2017;71:447–61.
- Babjuk M, Böhle A, Burger M, Compérat EM, Kaasinen J, Palou M, et al. EAU-guidelines: non-muscle invasive bladder cancer; 2016. Available from: www.uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
- Divrik T, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective clinical trial. J Urol 2006;175:1641–4.
- Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010;58:185–90.
- Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. BJU Int 2016;118:44–52.
- Sfakianos JP, Kim PH, Hakimi AA, Herr HW. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. J Urol 2014;191:341–5.
- Dogantekin E, Girgin C, Görgel SN, Soylemez H, Dinçel Ç. Can immediate second resection be an alternative to standardized second transurethral resection of bladder tumors? Kaohsiung J Med Sci 2016;32:147–51.
- Kim W, Song C, Park S, Kim SC, Cho YM, Hong B, Ahn H. Value of immediate second resection of the tumor bed to improve the effectiveness of transurethral resection of bladder tumor. J Endourol 2012;26:1059–64.
- Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 2005;174:2134–7.
- Hemdan T, Johansson R, Jahnson S, Hellström P, Tasdemir I, Malmström PU. 5-year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer. J Urol 2014;191:1244–9.
- Holmäng S, Hedelin H, Anderström C, Holmberg E, Johansson SL. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol 1997;157:800–3.
- Soukup V, Duskova J, Pesl M, Čapoun O, Feherová Z, Zámečník L, et al. The prognostic value of T1 bladder cancer substaging: a single institution retrospective study. Urol Int 2014;92:150–6.
- van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders GJ, Bostrom PJ, et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61:378–84.
- Katumalla FS, Devasia A, Kumar R, Kumar S, Chacko N, Kekre N. Second transurethral resection in T1G3 bladder cancer: selectively avoidable? Indian J Urol 2011;27:176–9.
- Olsson H, Hultman P, Rosell J, Jahnson S. Population-based study on prognostic factors for recurrence and progression in primary stage T1 bladder tumours. Scand J Urol 2013;47:188–95.
- Andius P, Johansson SL, Holmäng S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 2007;70:758–62.
- Beltran AL, Cheng L, Montironi R, Blanca A, Leva M, Rouprêt M, et al. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Arch 2014;465:199–205.
- Jancke G, Rosell J, Jahnson S. Impact of surgical experience on recurrence and progression after transurethral resection of bladder tumour in non-muscle-invasive bladder cancer. Scand J Urol 2014;48:276–83.
- Chamie K, Ballon-Landa E, Bassett JC, Daskivich TJ, Leventhal M, Deapen D, Litwin MS. Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link. Cancer 2015;121:379–85.
- Shindo T, Masumori N, Fukuta F, Miyamoto S, Tsukamoto T. Is T1G3 bladder cancer having a definite muscle layer in TUR specimens a highly progressive disease? Jpn J Clin Oncol 2010;40:153–6.
- Golabek T, Palou J, Rodriguez O, Gaya JM, Breda A, Villavicencio H. Is it possible to stop follow-up of patients with primary T1 G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy? World J Urol 2017;35:237–43.
- van Rhijn BW, van der Kwast TH, Kakiashvili DM, Fleshner NE, van der Aa MN, Alkhateeb S, et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int 2010;106:206–11.